ADVFN - Advanced Financial Network.
HOME» NYSE » G » GSK Stock Price » GSK Stock News

Glaxosmithkline Share News

 Glaxosmithkline Stock Price
GSK Stock Price
 Glaxosmithkline Stock Chart
GSK Stock Chart
 Glaxosmithkline Stock News
GSK Stock News
 Glaxosmithkline Company Information
GSK Company Information
 Glaxosmithkline Stock Trades
GSK Stock Trades

AstraZeneca Needs To Replenish Drug Pipeline - Chairman

By Marta Falconi ZURICH--AstraZeneca PLC (AZN) aims to replenish its thin pipeline of new drugs through external collaborations and by buying drugs in late stages of development from other drugmakers, Chairman Leif Johansson said in an interview Tuesday. His comments come after the company announced it appointed former Roche head of pharma, Pascal Soriot, as chief executive, to succeed David Brennan, who earlier this year retired abruptly amid shareholder dissatisfaction with the company's performance. "There's a number of medicines going off patent," Mr. Johansson said. "We need to replenish them." The U.K.'s No. 2 drug maker by sales, after GlaxoSmithKline PLC (GSK), has suffered a number of expensive drug-development failures, and shown a poor track record in bringing new medicines to market, analysts say. Some of AstraZeneca's biggest drugs are facing, or will soon face, competition from low-cost generics. Mr. Johansson also said that while the pharmaceutical sector is facing challenges, there are also opportunities, such as the possibility of buying buy late-stage drugs, emerging markets and advances in science, including genome technology, which he touted as a way to learn how the human body works and possibly help find new drugs. Write to Marta Falconi at marta.falconi@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Glaxosmithkline (GSK)
DateTimeHeadline
02/10/201609:03:55Report of Foreign Issuer (6-k)
02/09/201603:40:00Sanofi Profit Hit By Falling Diabetes Revenue
02/03/201613:15:38Report of Foreign Issuer (6-k)
02/03/201611:04:00Investors' Fears Eased as Glaxo Posts Solid Results -- Update
02/03/201608:30:00GlaxoSmithKline Posts $510 Million Net Loss
02/03/201608:23:00GlaxoSmithKline Posts GBP354 Million Net Loss in 4Q
02/02/201609:44:00GSK Submits Application to Expand Indication for FluLaval Flu...
02/02/201608:16:55Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
02/02/201606:27:35Report of Foreign Issuer (6-k)
02/01/201613:35:39Report of Foreign Issuer (6-k)
02/01/201613:28:08Report of Foreign Issuer (6-k)
02/01/201609:37:40Report of Foreign Issuer (6-k)
02/01/201609:30:00Report of Foreign Issuer (6-k)
02/01/201609:28:00Glaxosmithkline plc 4Q 2015 -- Forecast
02/01/201609:24:23Report of Foreign Issuer (6-k)
02/01/201609:19:41Report of Foreign Issuer (6-k)
02/01/201609:14:56Report of Foreign Issuer (6-k)
01/26/201614:13:49Amended Statement of Ownership (sc 13g/a)
01/22/201611:26:47Report of Foreign Issuer (6-k)
01/21/201611:04:35Report of Foreign Issuer (6-k)

Glaxosmithkline and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad